https://m2.mtmt.hu/ eng 2026-09-23 03:38 JournalArticle 33091346 VALIDATED true Population Health Research Institute, McMaster University, Hamilton, ON, Canada Hospital Universitari Vall d´Hebron, Barcelona, Spain National Cerebral and Cardiovascular Center, Osaka, Japan Semmelweis University, Budapest, Hungary Hospital of the University of Pennsylvania, Philadelphia, PA, United States Oregon Health and Science University, Portland, OR, United States National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece University of Thessaly, Larissa, Greece Institute of Psychiatry and Neurology, Warsaw, Poland University of Alberta Hospital, Edmonton, AB, Canada University of Paris, Bichat Hospital, Paris, France Dept Neurology and Center for Stroke Research Berlin, Charité- Universitätsmedizin Berlin, Berlin, Germany University Duisburg-Essen, Essen, Germany Vanderbilt University Medical Center, Nashville, TN, United States Bristol Myers Squibb, Princeton, NJ, United States The University of Western AustraliaPerth, Australia Perron Institute for Neurological and Translational SciencePerth, Australia Cited By :1 Export Date: 6 January 2023 CODEN: JSCDF Correspondence Address: Sharma, M.; Population Health Research Institute, DBCVSRI C4-120, 237 Barton Street East, Canada; email: mike.sharma@phri.ca Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; blood clotting factor 11, 9013-55-2; blood clotting factor 9, 9001-28-9; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8, 120202-65-5, 120202-67-7, 894353-16-3, 744256-69-7; milvexian, 1802425-99-5; blood clotting factor 11a; Aspirin; Clopidogrel; Factor XIa; Fibrinolytic Agents; Platelet Aggregation Inhibitors 0 false 2026-05-22T03:51:26.028+0000 2022-11-04T09:20:52.941+0000 2022-09-13T11:44:20.154+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Márta Molnár-Taga (SE 4-es admin) true 10062250 2025-04-14T16:28:42.935+0000 2022-11-04T09:20:53.198+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Article (Journal Article) 101 true 10000059 true 1 /api/category/1 Category Scientific true 1 Sharma, M. true true /api/journal/10006074 REVIEWED JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES 1052-3057 1532-8511 true false 10006074 false 10006074 true 1052-3057 1532-8511 Journal FOREIGN 31 10 106742 106742 12 2022 Background: Individuals with ischemic stroke or transient ischemic attack (TIA) have a high early risk of ischemic stroke despite dual antiplatelet therapy. The risk of ischemic stroke, and associated disability, represents a significant unmet clinical need. Genetic variants resulting in reduced factor XI levels are associated with reduced risk for ischemic stroke but are not associated with increased intracranial bleeding. Milvexian is an oral small-molecule inhibitor of FXIa that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets. Methods: We began a phase II, double-blinded, randomized, placebo-controlled trial at 367 sites in 2019. Participants (N = 2366) with ischemic stroke (National Institutes of Health Stroke Scale score ≤7) or high-risk TIA (ABCD2 score ≥6) were randomized to 1 of 5 doses of milvexian or placebo for 90 days. Participants also received clopidogrel 75 mg daily for the first 21 days and aspirin 100 mg for 90 days. The efficacy endpoint was the composite of ischemic stroke or incident infarct on magnetic resonance imaging. Major bleeding, defined as type 3 or 5 bleeding according to the Bleeding Academic Research Consortium, was the safety endpoint. Participant follow-up will end in 2022. Conclusion: The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA. © 2022 true true 2022 true true true false true false GREEN 2026-05-22 true https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742 39 0 39 34 1 39 39 36 37 39 39 34 34 34 5 0 39 34 39 34 0 4 4 Folyóiratcikk Journal Article 24 39 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 1 1 1 1 2023 0 18 16 18 16 2024 0 15 12 15 12 2025 0 4 4 4 4 2026 0 1 1 1 1 Q1 false false false false 2022-09-12T11:53:20.141+0000 Neurológiai Klinika (SE / AOK / K) 1 10 1 19 0 true Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 103387452 /api/authorship/103387452 Sharma, M. ✉ 1 0.05263158 true false true Sharma M. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387453 /api/authorship/103387453 Molina, C.A. 2 0.05263158 false false false Molina C.A. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387454 /api/authorship/103387454 Toyoda, K. 3 0.05263158 false false false Toyoda K. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387455 /api/authorship/103387455 Bereczki, D. [Bereczki, Dániel (Stroke), author] Department of Neurology (SU / FM / C) 4 0.053 false false false Author 10000800 /api/author/10000800 Dániel Bereczki (Stroke) Bereczki Dániel true 10000800 true Bereczki D. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387456 /api/authorship/103387456 Kasner, S.E. 5 0.05263158 false false false Kasner S.E. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387457 /api/authorship/103387457 Lutsep, H.L. 6 0.05263158 false false false Lutsep H.L. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387458 /api/authorship/103387458 Tsivgoulis, G. 7 0.05263158 false false false Tsivgoulis G. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387459 /api/authorship/103387459 Ntaios, G. 8 0.05263158 false false false Ntaios G. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387460 /api/authorship/103387460 Czlonkowska, A. 9 0.05263158 false false false Czlonkowska A. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387461 /api/authorship/103387461 Shuaib, A. 10 0.05263158 false false false Shuaib A. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387462 /api/authorship/103387462 Amarenco, P. 11 0.05263158 false false false Amarenco P. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387463 /api/authorship/103387463 Endres, M. 12 0.05263158 false false false Endres M. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387464 /api/authorship/103387464 Diener, H.C. 13 0.05263158 false false false Diener H.C. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387465 /api/authorship/103387465 Gailani, D. 14 0.05263158 false false false Gailani D. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387466 /api/authorship/103387466 Kahl, A. 15 0.05263158 false false false Kahl A. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387467 /api/authorship/103387467 Donovan, M. 16 0.05263158 false false false Donovan M. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387468 /api/authorship/103387468 Perera, V. 17 0.05263158 false false false Perera V. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387469 /api/authorship/103387469 Li, D. 18 0.05263158 false false false Li D. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 103387470 /api/authorship/103387470 Hankey, G.J. 19 0.05263158 false true false Hankey G.J. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PublicationIdentifier 21675237 /api/publicationidentifier/21675237 DOI: 10.1016/j.jstrokecerebrovasdis.2022.106742 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GREEN true IDENTICAL 10.1016/j.jstrokecerebrovasdis.2022.106742 https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742 false true PublicationIdentifier 21983583 /api/publicationidentifier/21983583 WoS: 000864176400018 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000864176400018 https://www.webofscience.com/wos/woscc/full-record/000864176400018 true true PublicationIdentifier 21675236 /api/publicationidentifier/21675236 Scopus: 85136586231 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85136586231 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85136586231 false true PublicationIdentifier 21675296 /api/publicationidentifier/21675296 PubMed: 36037679 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 36037679 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36037679&dopt=Abstract false true Classification 12162 /api/classification/12162 Neurology true true Keyword 52 /api/keyword/52 Adult true 52 true Keyword 56 /api/keyword/56 Female true 56 true Keyword 62 /api/keyword/62 Male true 62 true Keyword 1699 /api/keyword/1699 ARTICLE true 1699 true Keyword 3122 /api/keyword/3122 human true 3122 true Keyword 4196 /api/keyword/4196 Treatment Outcome true 4196 true Keyword 4602 /api/keyword/4602 major clinical study true 4602 true Keyword 4608 /api/keyword/4608 controlled study true 4608 true Keyword 5084 /api/keyword/5084 dose response true 5084 true Keyword 5785 /api/keyword/5785 cerebrovascular accident true 5785 true Keyword 5799 /api/keyword/5799 nuclear magnetic resonance imaging true 5799 true Keyword 5924 /api/keyword/5924 randomized controlled trial true 5924 true Keyword 5929 /api/keyword/5929 clinical trial true 5929 true Keyword 8845 /api/keyword/8845 Acute Disease true 8845 true Keyword 13979 /api/keyword/13979 human cell true 13979 true Keyword 14247 /api/keyword/14247 phase 2 clinical trial true 14247 true Keyword 14268 /api/keyword/14268 placebo true 14268 true Keyword 14299 /api/keyword/14299 drug safety true 14299 true Keyword 14300 /api/keyword/14300 drug efficacy true 14300 true Keyword 14301 /api/keyword/14301 double blind procedure true 14301 true Keyword 14467 /api/keyword/14467 thrombocyte true 14467 true Keyword 15151 /api/keyword/15151 transient ischemic attack true 15151 true Keyword 15488 /api/keyword/15488 acetylsalicylic acid true 15488 true Keyword 17441 /api/keyword/17441 stroke true 17441 true Keyword 17807 /api/keyword/17807 ischemic stroke true 17807 true Keyword 20203 /api/keyword/20203 follow up true 20203 true Keyword 1000031 /api/keyword/1000031 Stroke prevention true 1000031 true Keyword 1001043 /api/keyword/1001043 MRI true 1001043 true Keyword 1003524 /api/keyword/1003524 Clopidogrel true 1003524 true Keyword 1003558 /api/keyword/1003558 antithrombocytic agent true 1003558 true Keyword 1006295 /api/keyword/1006295 randomized trial true 1006295 true Keyword 1009029 /api/keyword/1009029 risk reduction true 1009029 true Keyword 1016421 /api/keyword/1016421 bleeding true 1016421 true Keyword 1020053 /api/keyword/1020053 thromboembolism true 1020053 true Keyword 1028182 /api/keyword/1028182 brain infarction true 1028182 true Keyword 1028795 /api/keyword/1028795 blood clotting factor 9 true 1028795 true Keyword 1029668 /api/keyword/1029668 drug selectivity true 1029668 true Keyword 1034506 /api/keyword/1034506 anticoagulant agent true 1034506 true Keyword 1142804 /api/keyword/1142804 National Institutes of Health Stroke Scale true 1142804 true Keyword 1495334 /api/keyword/1495334 Dual antiplatelet therapy true true Keyword 1510599 /api/keyword/1510599 ABCD2 score true true Keyword 1515835 /api/keyword/1515835 Factor XI true true Keyword 1515836 /api/keyword/1515836 blood clotting factor 11 true true Keyword 1967198 /api/keyword/1967198 blood clotting factor 11a inhibitor true true Keyword 2630514 /api/keyword/2630514 milvexian true true Keyword 2630514 /api/keyword/2630514 milvexian true true SjrRating 11318572 /api/sjrrating/11318572 sjr:Q1 (2022) Scopus - Rehabilitation JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES 1052-3057 1532-8511 27 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2742 /api/classificationexternal/2742 Scopus - Rehabilitation true 2742 true Q1 DIRECT true true Reference 33537485 /api/reference/33537485 1. July 12-14, p. 2020 1 false true Reference 33537462 /api/reference/33537462 2. Johnston, S.C., Easton, J.D., Farrant, M., Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (2018) N Engl J Med, 379 (3), pp. 215-225 2 false true Reference 33537463 /api/reference/33537463 3. Xu, J., Wang, A., Wangqin, R., Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile (2019) Ann Neurol, 86 (3), pp. 419-426 3 false true Reference 33537464 /api/reference/33537464 4. Wang, Y., Meng, X., Wang, A., Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA (2021) N Engl J Med, 385 (27), pp. 2520-2530 4 false true Reference 33537465 /api/reference/33537465 5. Johnston, S.C., Amarenco, P., Denison, H., Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA (2020) N Engl J Med, 383 (3), pp. 207-217 5 false true Reference 33537466 /api/reference/33537466 6. Toyoda, K., Uchiyama, S., Yamaguchi, T., Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial (2019) Lancet Neurol, 18 (6), pp. 539-548 6 false true Reference 33537467 /api/reference/33537467 7. Tan, C.H., Wu, A.G., Sia, C.H., Cilostazol for secondary stroke prevention: systematic review and meta-analysis (2021) Stroke Vasc Neurol, 6 (3), pp. 410-423 7 false true Reference 33537468 /api/reference/33537468 8. Hart, R.G., Diener, H.C., Coutts, S.B., Embolic strokes of undetermined source: the case for a new clinical construct (2014) Lancet Neurol, 13 (4), pp. 429-438 8 false true Reference 33537469 /api/reference/33537469 9. Capodanno, D., Bhatt, D.L., Eikelboom, J.W., Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease (2020) Nat Rev Cardiol, 17 (4), pp. 242-257 9 false true Reference 33537470 /api/reference/33537470 10. Mega, J.L., Braunwald, E., Wiviott, S.D., Rivaroxaban in patients with a recent acute coronary syndrome (2012) N Engl J Med, 366 (1), pp. 9-19 10 false true Reference 33537471 /api/reference/33537471 11. Eikelboom, J.W., Connolly, S.J., Bosch, J., Rivaroxaban with or without aspirin in stable cardiovascular disease (2017) N Engl J Med, 377 (14), pp. 1319-1330 11 false true Reference 33537472 /api/reference/33537472 12. Sharma, M., Hart, R.G., Connolly, S.J., Stroke outcomes in the COMPASS trial (2019) Circulation, 139 (9), pp. 1134-1145 12 false true Reference 33537473 /api/reference/33537473 13. Perera, K.S., Ng, K.K.H., Nayar, S., Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial (2020) JAMA Neurol, 77 (1), pp. 43-48 13 false true Reference 33537474 /api/reference/33537474 14. Fredenburgh, J.C., Weitz, J.I., Factor XI as a target for new anticoagulants (2021) Hamostaseologie, 41 (2), pp. 104-110 14 false true Reference 33537475 /api/reference/33537475 15. Gill, D., Georgakis, M.K., Laffan, M., Genetically determined FXI (Factor XI) levels and risk of stroke (2018) Stroke, 49 (11), pp. 2761-2763 15 false true Reference 33537476 /api/reference/33537476 16. Salomon, O., Steinberg, D.M., Koren-Morag, N., Tanne, D., Seligsohn, U., Reduced incidence of ischemic stroke in patients with severe factor XI deficiency (2008) Blood, 111 (8), pp. 4113-4117 16 false true Reference 33537477 /api/reference/33537477 17. Rohmann, J.L., Huo, S., Sperber, P.S., Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke (2020) J Thromb Haemost, 18 (12), pp. 3316-3324 17 false true Reference 33537478 /api/reference/33537478 18. Duga, S., Salomon, O., Congenital factor XI deficiency: an update (2013) Semin Thromb Hemost, 39 (6), pp. 621-631 18 false true Reference 33537479 /api/reference/33537479 19. Buller, H.R., Bethune, C., Bhanot, S., Factor XI antisense oligonucleotide for prevention of venous thrombosis (2015) N Engl J Med, 372 (3), pp. 232-240 19 false true Reference 33537480 /api/reference/33537480 20. Weitz, J.I., Bauersachs, R., Becker, B., Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial (2020) JAMA, 323 (2), pp. 130-139 20 false true Reference 33537481 /api/reference/33537481 21. Weitz, J.I., Strony, J., Ageno, W., Milvexian for the prevention of venous thromboembolism (2021) N Engl J Med, 385 (23), pp. 2161-2172 21 false true Reference 33537482 /api/reference/33537482 22. Dilger, A.K., Pabbisetty, K.B., Corte, J.R., Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy (2022) J Med Chem, 65 (3), pp. 1770-1785 22 false true Reference 33537483 /api/reference/33537483 23. Wong, P.C., Crain, E., Dilger, A., Small-molecule factor XIa inhibitor, BMS-986177/JNJ70033093, Prevents and treats arterial thrombosis in rabbits at doses that preserve hemostatic (2020) Res Pract Thromb Haemost, 4, p. 52 23 false true Reference 33537484 /api/reference/33537484 24. Wang, X., Qiu, L., Du, F., Shukla, N., Nawrocki, A., Chintala, M., Antithrombotic effects of a novel small molecule FXIa inhibitor BMS-986177/JNJ-70033093 in a rabbit AV-shunt model of thrombosis (2020) Poster PB0179. Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress 24 false true Reference 33537486 /api/reference/33537486 25. Perera, V., Wang, Z., Luettgen, J., First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor (2021) Clin Transl Sci, 15 (2), pp. 330-342 25 false true Reference 33537487 /api/reference/33537487 26. Perera, V., Wang, Z., Lubin, S., Pharmacokinetic and pharmacodynamic effects of coadministration of rifampin and BMS-986177/JNJ-70033093, an oral, direct, reversible, small molecule factor XIa inhibitor (2021) Clinic Pharmacol Therap, 109, p. S73 26 false true Reference 33537488 /api/reference/33537488 27. Perera, V., Wang, Z., Lubin, S., Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor (2022) Cardiol Ther 27 false true Reference 33537489 /api/reference/33537489 28. Perera, V., Abelian, G., Li, D., Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment (2022) Clin Pharmacokinet 28 false true Reference 33537490 /api/reference/33537490 29. Perera, V., Abelian, G., Li, D., Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants (2022) Clin Pharmacokinet, 61 (6), pp. 857-867 29 false true Reference 33537491 /api/reference/33537491 30. Johnston, S.C., Rothwell, P.M., Nguyen-Huynh, M.N., Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack (2007) Lancet, 369 (9558), pp. 283-292 30 false true Reference 33537492 /api/reference/33537492 31. Mehran, R., Rao, S.V., Bhatt, D.L., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium (2011) Circulation, 123 (23), pp. 2736-2747 31 false true Reference 33537493 /api/reference/33537493 32. Bornkamp, B., Pinheiro, J., Bretz, F., R: DoseFinding package, ver 0.9-16. Comprehensive R Archive Network (2018) 32 false true Reference 33537494 /api/reference/33537494 33. https://cran.r-project.org/, Cran.r-project. The Comprehensive R Archive Network 33 false true Reference 33537495 /api/reference/33537495 34. Bretz, F., Pinheiro, J.C., Branson, M., Combining multiple comparisons and modeling techniques in dose-response studies (2005) Biometrics, 61 (3), pp. 738-748 34 false true Reference 33537496 /api/reference/33537496 35. Pinheiro, J., Bornkamp, B., Glimm, E., Bretz, F., Model-based dose finding under model uncertainty using general parametric models (2014) Stat Med, 33 (10), pp. 1646-1661 35 false true Reference 33537497 /api/reference/33537497 36. von Kummer, R., Broderick, J.P., Campbell, B.C., The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy (2015) Stroke, 46 (10), pp. 2981-2986 36 false true /api/publication/33091346 Sharma M. et al. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. (2022) JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES 1052-3057 1532-8511 31 10<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Sharma M. ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Molina C.A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Toyoda K. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000800"><a href="/gui2/?type=authors&mode=browse&sel=10000800" target="_blank">Bereczki D. (<span class="authorship-author-name">Bereczki Dániel</span> <span class="authorAux-mtmt"> Stroke</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Neurology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kasner S.E. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Lutsep H.L. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Tsivgoulis G. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Ntaios G. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Czlonkowska A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Shuaib A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Amarenco P. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Endres M. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Diener H.C. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Gailani D. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kahl A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Donovan M. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Perera V. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Li D. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hankey G.J. </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;33091346" target="_blank">Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention</a></div> <div> <span class="journal-title">JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1052-3057">1052-3057</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1532-8511">1532-8511</a>)</span>: <span class="journal-volume">31</span> <span class="journal-issue">10</span> <span class="page"> Paper 106742. 12 p. </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="10.1016/j.jstrokecerebrovasdis.2022.106742" target="_blank" href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000864176400018" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000864176400018"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85136586231" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85136586231"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="36037679" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36037679&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Rehabilitation&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Surgery&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Cardiology and Cardiovascular Medicine&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> <div class="journal-subject">Journal subject: Scopus - Neurology (clinical)&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 39</span> | Independent citation: 34 | Self citation: 5 | Unknown citation: 0 | Number of citations in WoS: 36 | Number of citations in Scopus:&nbsp;37 | WoS/Scopus assigned:&nbsp;39 | Number of citations with DOI:&nbsp;39 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;33091346&sort=publishedYear,desc&sort=title"> Number of cited publications: 4 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 33091346</span> | <span class="status-data status-VALIDATED"> Validated </span> Core Citing | <span class="type-subtype">Journal Article ( Article ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Last Modified: 2022.11.04. 10:20 Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Comments</u>: Population Health Research Institute, McMaster University, Hamilton, ON, Canada Hospital Universitari Vall d´Hebron, Barcelona, Spain National Cerebral and Cardiovascular Center, Osaka, Japan Semmelweis University, Budapest, Hungary Hospital of the University of Pennsylvania, Philadelphia, PA, United...</pre> </div></div>